Alzheimer’s Disease & Dementia
These data indicate that cortisol levels may contribute to the cognitive decline observed in elderly adults with late-life depression.
These findings have high clinical relevance because patients with apathy are likely to withdraw from care.
Drinking sugary beverages has been previously linked to markers of preclinical Alzheimer disease, but the risk associated with consuming added sugars is not established.
In the previous SPRINT study, researchers compared an intensive BP reduction strategy (target systolic BP <120 mmHg) vs standard BP reduction strategy (target systolic BP <140 mmHg).
Although treatment with nabilone significantly improved agitation, cognition, and nutrition, the authors cautioned that sedation should be closely monitored.
Participants were drawn from the Health and Retirement Study, which provided multiple observations, genetic information, and previous alcohol use.
Given the lack of differences seen via the NIS, the authors suggested that subjective questionnaires may not be a trustworthy method to assess possible statin-associated cognitive deficits.
Results showed that most common NSAIDs, including aspirin, ibuprofen, naproxen, and celecoxib, did not alter cognitive degeneration in patients with mild cognitive impairment or Alzheimer disease.
The genetically-mediated effects of angiotensin-converting enzyme (ACE) inhibitors showed an improvement in cognition in patients with Alzheimer disease dementia but not in functionality.
The analysis suggests a beneficial effect of aducanumab on functional and cognitive domain scores in adults with Alzheimer disease.
Memantine Plus Cholinesterase Inhibitors Improves Psychosis, Neurobehavioral Symptoms in Alzheimer DiseaseJuly 25, 2018
Investigators pooled data from patients from 3 phase 3, 24-week, randomized, placebo-controlled trials of MEM in patients with Alzheimer disease receiving concurrent ChEIs.
As the neurodegenerative processes of Alzheimer disease and Parkinson disease are different, early cognitive impairment also present differently in these diseases.
Given the frequent use of benzodiazepines among older people, even a small increase in absolute risk may be a serious matter on a population level.
Phase 3 clinical trials for lanabecestat (Eli Lilly and AstraZeneca), an investigational Alzheimer disease treatment, are being discontinued for futility.
The lifetime risks of Alzheimer disease dementia vary considerably by age, gender, and the preclinical or clinical disease state.
There is a reduced risk for dementia for older Chinese adults actively participating in intellectual activities.
Public health strategies for preventing dementia should target socioeconomic gaps to reduce health disparities and protect the disadvantaged.
The researchers encouraged clinicians not to rely solely on medication to treat midlife anxiety, as benzodiazepines have been shown to increase mortality in certain groups; they pointed to talk therapy, meditation, and mindfulness-based interventions as possible considerations.
Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.
Clinicians should take depression into careful consideration when treating patients with Alzheimer dementia, as the two conditions combined may predispose patients to cardiovascular disease more than either condition alone.
These findings indicate that anxiety may be a risk factor for late-life dementia, excluding anxiety that is related to prodromal cognitive decline.
These results suggest that antipsychotic exposure has no impact on relative mortality.
These data support the importance of TBI preventative measures and proper management strategies for subsequent dementia.
The findings also suggested that more a more recent diagnosis of psychosis was a greater predictor of the development of dementia, as opposed to cases where patients had been living with psychotic disorder diagnoses for 10 years or more.
Patients with a phonemic advantage at baseline should be followed more closely with a higher index of suspicion for progression to Alzheimer disease.
Investigators evaluated CSF Aβ1-42 levels obtained from individuals who presented no signs of cognitive dysfunction at enrollment and estimated the proximity of participants' age to their parents' age of AD symptom onset.
Spouses who are affected by dementia may benefit from an at-home dyadic, relationship-focused psychoeducational intervention.
These findings support the recognition of alcohol use disorders as a major risk factor for all dementia types.
There are a handful of biomarkers that offer potential value for predicting the risk for development of MCI symptoms from AD symptoms.
The researchers noted that automated tests should not be used alone, but should instead be used as part of a comprehensive evaluation that must include clinical judgment and involve traditional assessor-guided cognitive batteries.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age